Építés alatt – nem éles oldal
Belépés
Taking people in Dánia4. fázis

NICardipine for Fast Achievement of Systolic BP Targets in ICH

Key facts

Where
Aarhus, DániaSee the site
Phase
4. fázis

Where in Dánia

  • Aarhus University HospitalAarhus, DániaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Aarhus University Hospital
Trial code
NCT07044232
Record updated
2026. június 24.
Original description
Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP <140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.Read full original descriptionShow less

NICardipine for Fast Achievement of Systolic BP Targets in ICH - a Quasi-randomized, Implementation Trial With Stepwise Rollout of Nicardipin Based Treatment of Hypertension.

Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP <140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.

Inclusion: Age ≥18 years; Acute spontaneous Intracerberal Hemorrhage confirmed by imaging; Symptom onset to stroke center admission <6 hours; Elevated systolic blood pressure (>140 mmHg) at admission.

Exclusion: Presumed fatal bleeding at admission; Secondary causes of ICH (e.g., trauma, vascular malformation); Short remaining life expectancy (<12 month).

ClinicalTrials.gov NCT07044232